Ht-Logo-gigapixel-icon
Search
Close this search box.
Ht-Logo-gigapixel-icon
Search
Close this search box.
Saturday, November 2, 2024
Canada’s Politics and Government News Source Since 1989
Latest Paper
Saturday, November 2, 2024 | Latest Paper
Subscribe Now

TRENDING:

Nigel Rawson and Brett Skinner

Nigel Rawson is an independent researcher in Saskatoon, Sask., and an affiliate scholar with the Canadian Health Policy Institute. Brett Skinner is CEO of the Canadian Health Policy Institute in Toronto.

Ongoing uncertainty about prices will deter new drug launches in Canada

  • In April, the federal minister of health announced that the government would not proceed with two of three major pieces in its new regulatory guidelines for the Patented Medicine
Opinion | BY NIGEL RAWSON AND BRETT SKINNER | September 7, 2022
Health Minister Jean-Yves Duclos speaks at an Aug. 23 press conference in Ottawa. Canada’s attractiveness as a marketplace for new medicines has already diminished as a result of uncertainty about the PMPRB changes, write Nigel Rawson and Brett Skinner. The Hill Times photograph by Andrew Meade

Ongoing uncertainty about prices will deter new drug launches in Canada

Opinion | BY NIGEL RAWSON AND BRETT SKINNER | September 7, 2022
  • In April, the federal minister of health announced that the government would not proceed with two of three major pieces in its new regulatory guidelines for the Patented Medicine

Ongoing uncertainty about prices will deter new drug launches in Canada

Opinion | BY NIGEL RAWSON AND BRETT SKINNER | September 7, 2022
  • In April, the federal minister of health announced that the government would not proceed with two of three major pieces in its new regulatory guidelines for the Patented Medicine
Health Minister Jean-Yves Duclos speaks at an Aug. 23 press conference in Ottawa. Canada’s attractiveness as a marketplace for new medicines has already diminished as a result of uncertainty about the PMPRB changes, write Nigel Rawson and Brett Skinner. The Hill Times photograph by Andrew Meade

Ongoing uncertainty about prices will deter new drug launches in Canada

  • In April, the federal minister of health announced that the government would not proceed with two of three major pieces in its new regulatory guidelines for the Patented Medicine
Opinion | BY NIGEL RAWSON AND BRETT SKINNER | September 7, 2022
Health Minister Jean-Yves Duclos speaks at an Aug. 23 press conference in Ottawa. Canada’s attractiveness as a marketplace for new medicines has already diminished as a result of uncertainty about the PMPRB changes, write Nigel Rawson and Brett Skinner. The Hill Times photograph by Andrew Meade

Ongoing uncertainty about prices will deter new drug launches in Canada

Opinion | BY NIGEL RAWSON AND BRETT SKINNER | September 7, 2022
  • In April, the federal minister of health announced that the government would not proceed with two of three major pieces in its new regulatory guidelines for the Patented Medicine

Ongoing uncertainty about prices will deter new drug launches in Canada

Opinion | BY NIGEL RAWSON AND BRETT SKINNER | September 7, 2022
  • In April, the federal minister of health announced that the government would not proceed with two of three major pieces in its new regulatory guidelines for the Patented Medicine
Health Minister Jean-Yves Duclos speaks at an Aug. 23 press conference in Ottawa. Canada’s attractiveness as a marketplace for new medicines has already diminished as a result of uncertainty about the PMPRB changes, write Nigel Rawson and Brett Skinner. The Hill Times photograph by Andrew Meade

Time for the PMPRB to go

  • Since its establishment in 1987, the Patented Medicine Prices Review Board (PMPRB), a quasi-judicial federal tribunal, has regulated prices of patented medicines. In 2017,
Opinion | BY NIGEL RAWSON AND BRETT SKINNER | June 17, 2021
The PMPRB is clearly annoyed by opposition to the regulation changes. According to an internal document made public by an access to information request from Conservative MP Tom Kmiec, pictured, the PMPRB believes “opponents of the reforms … are spreading disinformation through organized public relations campaigns.” The Hill Times photograph by Andrew Meade

Time for the PMPRB to go

Opinion | BY NIGEL RAWSON AND BRETT SKINNER | June 17, 2021
  • Since its establishment in 1987, the Patented Medicine Prices Review Board (PMPRB), a quasi-judicial federal tribunal, has regulated prices of patented medicines. In 2017,

Time for the PMPRB to go

Opinion | BY NIGEL RAWSON AND BRETT SKINNER | June 17, 2021
  • Since its establishment in 1987, the Patented Medicine Prices Review Board (PMPRB), a quasi-judicial federal tribunal, has regulated prices of patented medicines. In 2017,
The PMPRB is clearly annoyed by opposition to the regulation changes. According to an internal document made public by an access to information request from Conservative MP Tom Kmiec, pictured, the PMPRB believes “opponents of the reforms … are spreading disinformation through organized public relations campaigns.” The Hill Times photograph by Andrew Meade
More Stories

News

Get free news updates

Opinion

Submit a guest opinion article

resources

Advertise

get help

Subscribe
CloseMenu